Caron, Jérôme Pène, Véronique Tolosa, Laia Villaret, Maxime Luce, Eléanor Fourrier, Angélique Heslan, Jean-Marie Saheb, Samir Bruckert, Eric Gómez-Lechón, María Nguyen, Tuan Rosenberg, Arielle Weber, Anne Dubart-Kupperschmitt, Anne Additional file 1: of Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection Figure S1. Characterization of FH-iPSCs. (A) FH-iPSCs display the typical hESC-like morphology cultured on irradiated MEFs. (B) Representative RT-PCR for indicated stem cell markers in FH-iPSCs. (C) Representative FACS analyses for indicated stem cell markers in FH-iPSCs. Black lines indicate isotype control antibody and red lines, positive cell immunostaining. (D) Representative pictures of immunostainings for indicated stem cell markers in FH-iPSCs. Scale bars: 50 μm. (E) Karyotype analysis showed no genetic abnormalities induced by the correction process. (F) FH-iPSCs generated embryoid bodies expressing specific proteins of derivatives from the 3 embryonic germ layers: PAX6 (ectoderm), αSMA (mesoderm) and AFP (endoderm). (TIF 2224 kb) Cardiovascular disease;Genome editing;Cell models;Cell therapy;Gene therapy;Personalized medicine 2019-07-30
    https://springernature.figshare.com/articles/figure/Additional_file_1_of_Low-density_lipoprotein_receptor-deficient_hepatocytes_differentiated_from_induced_pluripotent_stem_cells_allow_familial_hypercholesterolemia_modeling_CRISPR_Cas-mediated_genetic_correction_and_productive_hepatitis_C_vi/9162950
10.6084/m9.figshare.9162950.v1